| Issue Date | Title | Author(s) |
| 2009 | The anti-apoptotic protein HAX-1 is a regulator of cardiac function | Zhao, Wen; Waggoner, Jason R.; Zhang, Zhi-Guo; Lam, Chi Keung; Han, Peidong; Qian, Jiang; Schroder, Paul M.; Mitton, Bryan; Kontrogianni-Konstantopoulos, Aikaterini; Robia, Seth L.; Kranias, Evangelia G. |
| 23-Nov-2021 | Detection of CSRP2 Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL | Cao, Lei-Ming; Wu, Li-Xin; Zhao, Ming-Yue; Zhou, Ya-Lan; Li, Jin-Lan; Sun, Qiu-Yu; Jiang, Hao; Qian, Jiang; Xu, Lan-Ping; Zhang, Xiao-Hui; Liu, Kai-Yan; Huang, Xiao-Jun; Ruan, Guo-Rui |
| 2017 | EIGENVALUE EMBEDDING OF UNDAMPED VIBROACOUSTIC SYSTEMS WITH NO-SPILLOVER | Qian, Jiang; Cai, Yunfeng; Chu, Delin; Tan, Roger C. E. |
| 2011 | The formulation and numerical method for partial quadratic eigenvalue assignment problems | Cai, Yun-Feng; Qian, Jiang; Xu, Shu-Fang |
| 2015 | A modified Schur method for robust pole assignment in state feedback control | Guo, Zhen-chen; Cai, Yun-feng; Qian, Jiang; Xu, Shu-fang |
| 2008 | Orthogonal basis selection method for robust partial eigenvalue assignment problem in second-order control systems | Xu, Shufang; Qian, Jiang |
| 2015 | Perturbation analysis of the extinction probability of a Markovian binary tree | Guo, Pei-Chang; Cai, Yun-Feng; Qian, Jiang; Xu, Shu-Fang |
| 2016 | Refined Schur Method for Robust Pole Assignment with Repeated Poles | Guo, Zhen-Chen; Qian, Jiang; Cai, Yun-feng; Xu, Shu-fang |
| 2012 | Robust partial pole assignment problem for high order control systems | Cai, Yun-Feng; Qian, Jiang; Xu, Shu-Fang |
| 2009 | Symmetric low-rank corrections to quadratic models | Qian, Jiang; Xu, Shu-Fang; Bai, Feng-Shan |
| 23-Nov-2021 | Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients | Chen, Miao; Bao, Li; Chen, Wenming; Fu, Rong; Guo, Rong; Jing, Hongmei; Liu, Hui; Liu, Qinhua; Ma, Yanping; Sun, Xiuli; Wang, Wei; Wang, Yafei; Yan, Xiaojing; Qian, Jiang; Zhuang, Junling |
| 23-Nov-2021 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) | Qian, Jiang; Shi, Dayu; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Song, Yongping; Zhang, Gongli; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yujun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 23-Nov-2021 | Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) | Qian, Jiang; Shi, Dayu; Li, Zongru; Qin, Yazhen; Zhao, Ting; Liu, Bingcheng; Chen, Zi; Niu, Qian; Men, Lichuang; Wang, Hengbang; Yang, Dajun; Zhai, Yifan; Huan, Xiaojun |
